Suppr超能文献

[通过定期输注凝血因子 VIII 在高反应性抑制物的甲型血友病患者中成功诱导免疫耐受及产生新型止血效果]

[Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].

作者信息

Shima M, Sawamoto Y, Kamisue M, Shibata Y, Tuzi S, Kuwabara M, Tanaka I, Tanizawa T, Tanaka A, Ueda M, Kakishita E, Yoshioka A

机构信息

Department of Pediatrics, Nara Medical University, Japan.

出版信息

Rinsho Ketsueki. 1996 Nov;37(11):1303-8.

PMID:8960666
Abstract

A hemophilia A patient with high responder inhibitor had been treated by (activated) prothrombin complex concentrates (A) PCC and activated factor VII until the occurrence of intracranial bleeding at the age of 6 years. Since the inhibitor titer was decreased less than 1 Bethesda Units/ml, high dose of factor VIII was given followed by the infusions of factor VIII concentrates (100 units/kg) three times a week. In spite of previous episodes of anamnestic responses by factor VIII products before, the inhibitor titer did not increase and disappeared completely 6 months after the FVIII infusion therapy. The specific anti-factor VIII IgG subclasses of the inhibitor were IgG2 and IgG4. The inhibitor recognized both light and heavy chains. He have no bleeding episode for 6 months since the beginning of the prophylactic with factor VIII concentrates.

摘要

一名高反应性抑制物的甲型血友病患者曾接受(活化)凝血酶原复合物浓缩剂(A)PCC和活化凝血因子VII治疗,直至6岁时发生颅内出血。由于抑制物滴度下降至低于1贝塞斯达单位/毫升,给予高剂量的凝血因子VIII,随后每周三次输注凝血因子VIII浓缩剂(100单位/千克)。尽管之前使用凝血因子VIII产品时有过回忆反应发作,但在凝血因子VIII输注治疗6个月后,抑制物滴度并未升高且完全消失。该抑制物的特异性抗凝血因子VIII IgG亚类为IgG2和IgG4。该抑制物可识别轻链和重链。自开始使用凝血因子VIII浓缩剂进行预防治疗以来,他已有6个月未发生出血事件。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验